{
    "id": 6463,
    "fullName": "NOTCH1 L1600Q",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NOTCH1 L1600Q lies within the HD-N domain of the Notch1 protein (PMID: 16738328). L1600Q results in increased Notch1 signaling in a reporter assay in one study (PMID: 28820917), but does not result in statistically significant increase of Notch1 signaling in another study (PMID: 27870570), and therefore, its effect on Notch1 protein function is unknown.",
            "references": [
                {
                    "id": 2752,
                    "pubMedId": 16738328,
                    "title": "Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16738328"
                },
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                },
                {
                    "id": 15963,
                    "pubMedId": 28820917,
                    "title": "Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28820917"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4851,
        "geneSymbol": "NOTCH1",
        "terms": [
            "NOTCH1",
            "AOS5",
            "AOVD1",
            "hN1",
            "TAN1"
        ]
    },
    "variant": "L1600Q",
    "createDate": "05/20/2015",
    "updateDate": "03/18/2020",
    "referenceTranscriptCoordinates": {
        "id": 143376,
        "transcript": "NM_017617",
        "gDna": "chr9:g.136504892A>T",
        "cDna": "c.4799T>A",
        "protein": "p.L1600Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21019,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs achieved a partial response after 2 doses of Brontictuzumab (OMP-52M51), however, his disease progressed shortly after treatment discontinuation (PMID: 27870570).",
            "molecularProfile": {
                "id": 35495,
                "profileName": "NOTCH1 L1600Q NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21021,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Sutent (sunitinib) treatment resulted in rapid disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs, and acquired FBXW7 W606* and NOTCH1 V1721G (PMID: 27870570).",
            "molecularProfile": {
                "id": 35498,
                "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21020,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, FBXW7 W606* and NOTCH1 V1721G were identified at disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs who was treated with Brontictuzumab (OMP-52M51) (PMID: 27870570).",
            "molecularProfile": {
                "id": 35498,
                "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6313,
            "profileName": "NOTCH1 L1600Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35495,
            "profileName": "NOTCH1 L1600Q NOTCH1 S2467fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35498,
            "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 143376,
            "transcript": "NM_017617",
            "gDna": "chr9:g.136504892A>T",
            "cDna": "c.4799T>A",
            "protein": "p.L1600Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}